华检医疗（1931.HK）

ETHK Labs Inc.
華檢醫療控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1931)

PROFIT WARNING

This announcement is made by ETHK Labs Inc. (the "**Company**", and together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform shareholders of the Company and potential investors that, based on preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2025 (the "**Year**") and information currently available to the Board, the Group is expected to report a consolidated profit attributable to owners of the Company for the Year of not more than approximately RMB42.2 million as compared to the consolidated profit attributable to the owners of the Company of approximately RMB260.4 million for the year ended 31 December 2024. The decrease in unaudited consolidated profit for the Year was mainly attributable to (i) a decrease in gross profit margin, which led to a decrease in gross profit of approximately RMB184.8 million, primarily impacted by a more competitive operating environment in the IVD industry; (ii) an increase in administrative expenses of approximately RMB68.0 million due to higher legal and professional fees incurred in connection with the Group's proposed dual listing in the United States, including fees paid to legal advisers, auditors, financial advisers, and other professional service providers engaged for the preparation of listing documents and related regulatory filings; and (iii) an increase in finance costs of approximately RMB24.5 million due to the increase in Group's borrowings to support its business expansion and working capital requirements, resulting in additional interest expenses.

As at the date of this announcement, the Company is still in the process of finalising the financial statements of the Group for the Year. The information contained in this announcement is only based on a preliminary assessment by the management of the Company with reference to the latest unaudited management accounts of the Group for the Year and the information currently available to the Board, which have not been reviewed or audited by the Company's auditors and/or the audit committee of the Company and are subject to possible adjustments arising from further review. The annual results announcement of the Company for the Year is expected to be published by the end of March 2026.

Shareholders of the Company and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
ETHK Labs Inc.
Lin Xianya
Executive Director

Hong Kong, 11 March 2026

As at the date of this announcement, the Board comprises three executive directors, namely, Mr. Lin Xianya, Mr. Chan Siu Kei Ken and Ms. Yi Xiao, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and three independent non-executive directors, namely, Dr. Zhong Renqian, Mr. Xu Da and Mr. Zhang Jianlei.

Certain figures set out in this announcement have been subject to rounding adjustment. The information contained in this announcement is based on a number of assumptions, current estimates and projections. The actual outcomes may differ. Nothing contained herein is, or shall be relied upon as, any measure, indicator, representation, or warranty of the Group's current or future operating or financial performance otherwise.